1. Home
  2. ACRV vs PVL Comparison

ACRV vs PVL Comparison

Compare ACRV & PVL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Acrivon Therapeutics Inc.

ACRV

Acrivon Therapeutics Inc.

HOLD

Current Price

$2.08

Market Cap

74.0M

Sector

Health Care

ML Signal

HOLD

Logo Permianville Royalty Trust Trust Units

PVL

Permianville Royalty Trust Trust Units

HOLD

Current Price

$1.80

Market Cap

59.7M

Sector

Energy

ML Signal

HOLD

Company Overview

Basic Information
Metric
ACRV
PVL
Founded
2018
2011
Country
United States
United States
Employees
N/A
N/A
Industry
Medicinal Chemicals and Botanical Products
Oil & Gas Production
Sector
Health Care
Energy
Exchange
Nasdaq
Nasdaq
Market Cap
74.0M
59.7M
IPO Year
2022
N/A

Fundamental Metrics

Financial Performance
Metric
ACRV
PVL
Price
$2.08
$1.80
Analyst Decision
Buy
Analyst Count
4
0
Target Price
★ $11.67
N/A
AVG Volume (30 Days)
★ 295.2K
57.1K
Earning Date
05-08-2026
03-20-2026
Dividend Yield
N/A
★ 7.43%
EPS Growth
★ 15.13
N/A
EPS
N/A
★ N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$568.17
N/A
P/E Ratio
★ N/A
$26.85
Revenue Growth
N/A
N/A
52 Week Low
$1.27
$1.58
52 Week High
$3.56
$2.01

Technical Indicators

Market Signals
Indicator
ACRV
PVL
Relative Strength Index (RSI) 54.90 46.98
Support Level $2.07 $1.73
Resistance Level $2.21 $1.84
Average True Range (ATR) 0.13 0.04
MACD 0.01 -0.01
Stochastic Oscillator 73.68 28.57

Price Performance

Historical Comparison
ACRV
PVL

About ACRV Acrivon Therapeutics Inc.

Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1; ACR-2316 a selective, dual WEE1/PKMYT1 inhibitor; and ACR-6840, a development candidate targeting CDK11. It has one reportable segment focused on the research and development of precision oncology therapies.

About PVL Permianville Royalty Trust Trust Units

Permianville Royalty Trust is a statutory trust which holds net profits interests in the profits from the sale of oil and natural gas production from non-operated assets of both conventional properties in the States of Texas, Louisiana, and New Mexico as well as unconventional assets in the Permian and Haynesville basins.

Share on Social Networks: